The global alzheimer’s therapeutics market is expected to reach USD 6.4 billion in 2024, according to a new report by Grand View Research. Some primary factors driving the market growth includes rising government initiatives in order to raise awareness levels among people.
Growing
knowledge about the Alzheimer’s disease (AD) and its high prevalence and
incidence in developing economies are few of the major drivers supporting the
market growth. Several governments, nonprofit, and private organizations
worldwide are actively engaged in increasing people’s awareness regarding
progressive AD, such as Alzheimer’s Association, the Alzheimer’s Society of
Canada, Alzheimer’s Europe organization, and various other small organizations.
Furthermore,
the increased government funding for providing better care and support to the
people with partial dementia is another important factor anticipated to enlarge
market growth. For instance, organizations like Florida Department of Health,
the National Institute of Health, and Alzheimer’s Association in partnership
with other private and government organizations provide funds to the research
centers.
The
presence of various pipeline drugs is anticipated to provide the market with
potential growth opportunities. For instance, LMTX by TauRx Pharmaceutical
Ltd.; idalopirdine (Lu AE58054) by Lundbeck; crenezumab by AC Immune SA; and
BAN2401 by Eisai
Moreover,
novel therapeutics with minimal dosage requirement has been introduced
resulting in cost-effective alternatives, which is further expected to boost
the market growth. For instance, Namzaric by Actavis was developed in two
forms: 10 mg and 28 mg. 10 mg requires to be administered twice a day, while 28
mg requires to be administered once in a day.
Full Research Report On Alzheimer’s Therapeutics Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/alzheimers-therapeutics-market
Further Key
Findings from the Study Suggest:
- The cholinesterase
inhibitors segment was dominant in 2013 but lost hold on the market till
2015. Patent expiry of key drugs such as Aricept, Exelon, and Razadyne was
the major factor for decline in market share.
- Exelon transdermal patch is
estimated to lose exclusivity in 2019. It is a highly prescribed drug for
the treatment of mild to moderate AD, which contributed toward its revenue
generation in 2015.
- N-methyl-D-aspartate
receptor antagonist, on the other hand, is expected to witness a
significant growth of around 16.0% over the forecast period owing to
introduction of extended relase formulation of Namenda.
- Other drug therapies such as
monocloclonal antibodies and drugs targeting Tau proteins are in being
studied in latter phases of the clinical trials. Presence of a strong of
pipeline drugs for target disease are attributing toward fastest growth of
these drugs
- North America dominated the
overall market in terms of revenue with share of over 33.0% in 2015, which
is majorly facilitated by the availability of sophisticated healthcare
facilities and infrastructure.
- Some key players operating
in this industry are Pfizer, Inc.; Merck & Co. Inc.; Novartis AG;
Eisai Co. Ltd., H. Lundbeck A/S, AC Immune; TauRx Pharmaceuticals Ltd.;
Actavis plc.; Forest Laboratories; and Teva Pharmaceuticals Industries
Ltd.
- Market players are expanding
their product portfolio by developing and launching generic versions of
drugs to sustain its market position. For instance, in 2015, Dr. Reddy’s
Laboratories Ltd. and Mylan launched the generic version of Namenda
(Forest laboratories – Actavis).
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/alzheimers-therapeutics-market/request/rs1
Grand View Research has segmented
the Alzheimer’s therapeutics market on the basis of drug class and region:
Alzheimer’s
Therapeutics Market Drug Outlook (Market Revenue in USD Million, 2013
- 2024)
- Cholinesterase Inhibitors
- N-methyl-D-aspartate (NMDA)
receptor antagonist
Alzheimer’s
Therapeutics Market Regional Outlook, (Market Revenue in USD Million, 2013
- 2024)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The company
provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment